Clinical Trial Update: Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 trial of trastuzumab in combination with AMG 479 for HER-2 overexpressing metastatic breast cancer progressing on trastuzumab has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AMG 479
• Trastuzumab (trastuzumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: WITHDRAWN